Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma, Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Conditions
Brief summary
This phase II trial studies how well pembrolizumab, ipilimumab, and aspirin work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab, ipilimumab, and aspirin may work better in treating patients with melanoma.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the overall response rate (ORR) by week 12 in patients with stage III unresectable/stage IV melanoma. SECONDARY OBJECTIVES: I. To determine the median progression free survival, overall survival, and toxicity profile of the combination of ipilimumab, pembrolizumab and high dose aspirin in patients with stage III unresectable/IV melanoma. OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin orally (PO) twice daily (BID) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days.
Interventions
DRUGAspirin
Given PO
BIOLOGICALIpilimumab
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
BIOLOGICALPembrolizumab
Given IV
Sponsors
Merck Sharp & Dohme LLC
University of California, San Francisco
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically confirmed melanoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 * Leukocytes \>= 3,000/microliter (mcL) * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin within normal institutional limits * Total bilirubin =\< 1.5 X institutional upper limit * Aspartate aminotransferase (AST) \[serum glutamic-oxaloacetic transaminase (SGOT)\] =\< 2.5 X institutional upper limit of normal * Alanine aminotransferase (ALT) \[serum glutamate pyruvate transaminase (SGPT)\] =\< 2.5 X institutional upper limit of normal * Creatinine =\< 1.5 X upper limit of normal (ULN) * Women of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study drug; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Women of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject * Men of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject * Ability to understand a written informed consent document, and the willingness to sign it
Exclusion criteria
* Any mental or physical condition or disease or past medical history that mitigates against following the protocol * History of active autoimmune diseases such as but not limited to Crohn?s disease, ulcerative colitis, Sjogren's syndrome, requiring active immune suppression; patient may have hay fever or controlled asthma * Any solid organ transplant or bone marrow transplant * Any other disseminated malignancy. Exceptions include: localized prostate cancer, basal or squamous cell skin cancer, localized cervical cancer, and localized breast cancer. * Uncontrolled central nervous system (CNS) metastasis; patients with CNS metastasis can be eligible if definitively treated with radiotherapy or surgery * Any coexistent medical condition interfering with drug absorption * History of gastritis or malabsorption syndrome or aspirin intolerance or allergy * Live vaccination within the last 30 days * History of multiple sclerosis, type 1 diabetes mellitus (DM) or Guillain-Barre syndrome * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to 12 weeks | Defined as the proportion of subjects for whom the best overall response at week 12 is confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST). Point estimates of ORR and 95% confidence intervals will be provided. Only participants with confirmed response are included in this analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Reported Treatment-related Adverse Events | Within 30 days after last dose of study drug, up to 3 years | Number of participants with reported treatment-related adverse events defined as having an attribution of definite, possible, and probable according to Common Terminology Criteria for Adverse Events (CTCAE) version 4 will be reported. |
| Proportion of Participants With Progression-free Survival (PFS) at 6 Months | Up to 6 months (182 days) | PFS at 6 months is defined as the proportion of subjects alive and progression-free 6 months (182 days) after study day 1. |
| Median Duration of PFS | Up to 3 years | Duration of PFS is defined as the time from the study day 1 to the earlier of disease progression or death due to any cause. The analysis of PFS will include only objective progression events per RECIST and clinical progression determined by the investigator may not be considered disease progression. The median duration of PFS will be estimated using the Kaplan-Meier methods with the associated 95% confidence interval. |
| Median Overall Survival (OS) | Up to 3 years | Duration of OS is defined as the time from study day 1 to death due to any cause. For subjects who are alive at the time of data cutoff or are permanently lost to follow-up, duration of OS will be right censored at the date the subject was last known to be alive. The median duration of OS will be estimated using the Kaplan-Meier methods with the associated 95% confidence interval. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Pembrolizumab, Ipilimumab, Aspirin) Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Aspirin: Given PO
Ipilimumab: Given IV
Laboratory Biomarker Analysis: Correlative studies
Pembrolizumab: Given IV | 27 |
| Total | 27 |
Baseline characteristics
| Characteristic | Treatment (Pembrolizumab, Ipilimumab, Aspirin) |
|---|---|
| Age, Customized 30-39 years old | 3 Participants |
| Age, Customized 40-49 years old | 3 Participants |
| Age, Customized 50-59 years old | 3 Participants |
| Age, Customized 60-69 years old | 8 Participants |
| Age, Customized 70-79 years old | 7 Participants |
| Age, Customized 80-89 years old | 3 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 25 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 26 Participants |
| Region of Enrollment United States | 27 participants |
| Sex: Female, Male Female | 9 Participants |
| Sex: Female, Male Male | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 4 / 27 |
| other Total, other adverse events | 26 / 27 |
| serious Total, serious adverse events | 3 / 27 |
Outcome results
Primary
Objective Response Rate (ORR)
Defined as the proportion of subjects for whom the best overall response at week 12 is confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST). Point estimates of ORR and 95% confidence intervals will be provided. Only participants with confirmed response are included in this analysis.
Time frame: Up to 12 weeks
Population: Only participants with confirmed response are included in this analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Pembrolizumab, Ipilimumab, Aspirin) | Objective Response Rate (ORR) | 0.522 proportion of participants |
Secondary
Median Duration of PFS
Duration of PFS is defined as the time from the study day 1 to the earlier of disease progression or death due to any cause. The analysis of PFS will include only objective progression events per RECIST and clinical progression determined by the investigator may not be considered disease progression. The median duration of PFS will be estimated using the Kaplan-Meier methods with the associated 95% confidence interval.
Time frame: Up to 3 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Pembrolizumab, Ipilimumab, Aspirin) | Median Duration of PFS | 7.6 months |
Secondary
Median Overall Survival (OS)
Duration of OS is defined as the time from study day 1 to death due to any cause. For subjects who are alive at the time of data cutoff or are permanently lost to follow-up, duration of OS will be right censored at the date the subject was last known to be alive. The median duration of OS will be estimated using the Kaplan-Meier methods with the associated 95% confidence interval.
Time frame: Up to 3 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Pembrolizumab, Ipilimumab, Aspirin) | Median Overall Survival (OS) | 8.9 months |
Secondary
Number of Participants With Reported Treatment-related Adverse Events
Number of participants with reported treatment-related adverse events defined as having an attribution of definite, possible, and probable according to Common Terminology Criteria for Adverse Events (CTCAE) version 4 will be reported.
Time frame: Within 30 days after last dose of study drug, up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Pembrolizumab, Ipilimumab, Aspirin) | Number of Participants With Reported Treatment-related Adverse Events | 5 particpants |
Secondary
Proportion of Participants With Progression-free Survival (PFS) at 6 Months
PFS at 6 months is defined as the proportion of subjects alive and progression-free 6 months (182 days) after study day 1.
Time frame: Up to 6 months (182 days)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Pembrolizumab, Ipilimumab, Aspirin) | Proportion of Participants With Progression-free Survival (PFS) at 6 Months | 0.566 proportion of participants |